Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ETCompany ParticipantsLaure Park - Senior Vice President ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

The talks are the latest sign of consolidation among real-estate brokerages during a prolonged period of lackluster home sales. The sale follows a more than year-long strategic review of the business.

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim v ...

Wachtell, Lipton, Rosen & Katz is steering Mallinckrodt Pharmaceuticals and Davis Polk & Wardwell is guiding Endo Inc. in ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

The combination of Mallinckrodt and Endo will create a strong pharmaceutical company with a diversified portfolio, enhanced ...